Respiratory Medicine
Volume 103, Issue 11 , Pages 1738-1745 , November 2009

Aerosol delivery of nebulised budesonide in young children with asthma

  • Karen G. Schueepp

      Affiliations

    • Swiss Paediatric Respiratory Research Group, Department of Pediatrics and Respiratory Medicine, University Children's Hospital, 3010 Berne, Switzerland
    • Corresponding Author InformationCorresponding author. Department of Paediatrics, University Children's Hospital, 3010 Bern, Switzerland. Tel.: +41 31 632 21 11; fax: +41 31 632 94 84.
    • ,
  • Sunalene G. Devadason

      Affiliations

    • Perth Medical Aerosol Research Group, University of Western Australia, School of Paediatrics and Child Health, Princess Margaret Children's Hospital, 6000 Perth, WA, Australia
    • ,
  • Christina Roller

      Affiliations

    • Perth Medical Aerosol Research Group, University of Western Australia, School of Paediatrics and Child Health, Princess Margaret Children's Hospital, 6000 Perth, WA, Australia
    • ,
  • Stefan Minocchieri

      Affiliations

    • Swiss Paediatric Respiratory Research Group, Department of Pediatrics and Respiratory Medicine, University Children's Hospital, 3010 Berne, Switzerland
    • ,
  • Alexander Moeller

      Affiliations

    • Swiss Paediatric Respiratory Research Group, Division of Respiratory Medicine, University Children's Hospital Zürich, 8032 Zürich, Switzerland
    • ,
  • Jürg Hamacher

      Affiliations

    • Pulmonary Medicine, Bern University Hospital, 3010 Berne, Switzerland
    • ,
  • Johannes H. Wildhaber

      Affiliations

    • Swiss Paediatric Respiratory Research Group, Department of Paediatrics, 1700 Fribourg, Switzerland

Received 12 June 2008 ,Accepted 30 April 2009.

References 

  1. Robinson PD, Van Asperen P. Asthma in childhood. Pediatr Clin North Am. 2009 Feb;56(1):191–226xii
  2. Allen DB, Bielory L, Derendorf H, et al. Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol. 2003;112(3 Suppl):S1–40
  3. Rau JL. The inhalation of drugs: advantages and problems. Respir Care. 2005;50(3):367–382
  4. Schuepp KG, Devadson S, Roller C, et al. A complementary combination of delivery device and drug formulation for inhalation therapy in preschool children. Swiss Med Wkly. 2004;134(13–14):198–200
  5. Dubus JC, Marguet C, Deschildre A, et al. Reseau de Recherche Clinique en Pneumonologie Pediatrique. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy. 2001;56:944–948
  6. Anhöj J, Bisgaard AM, Bisgaard H. Systemic activity of inhaled steroids in 1- to 3-year-old children with asthma. Pediatrics. 2002 Mar;109(3):E40
  7. Clay MM, Clarke SW. Effect of nebulised aerosol size on lung deposition in patients with mild asthma. Thorax. 1987 Mar;42(3):190–194E
  8. Clay MM, Pavia D, Clarke SW. Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects. Thorax. 1986 May;41(5):364–368
  9. Schuepp KG, Jauernig J, Janssens HM, et al. In vitro determination of the optimal particle size for nebulized aerosol delivery to infants. J Aerosol Med. 2005;18:225–235
  10. Janssens HM, van der Wiel EC, Verbraak AF, et al. Aerosol therapy and the fighting toddler: is administration during sleep an alternative?. J Aerosol Med. 2003 Winter;16(4):395–400
  11. Stangl R, Luangkhot N, Liening-Ewert R, et al. Characterising the first prototype of a vibrating membrane nebuliser. Respiratory Drug Delivery VII 2000, Palm Harbor; Proceedings: p. 455–58.
  12. Wildhaber JH, Devadason SG, Wilson JM, et al. Lung deposition of budesonide from turbuhaler in asthmatic children. Eur J Pediatr. 1998 Dec;157(12):1017–1022
  13. Roller CM, Zhang G, Troedson RG, et al. Spacer inhalation technique and deposition of extrafine aerosol in asthmatic children. Eur Respir J. 2007 Feb;29(2):299–306[Epub 2006 Sep 27]
  14. O'Doherty MJ, Thomas SH, Gibb D, et al. Lung deposition of nebulised pentamidine in children. Thorax. 1993 Mar;48(3):220–226
  15. Janssens HM, Krijgsman A, Verbraak TF, et al. Determining factors of aerosol deposition for four pMDI-spacer combinations in an infant upper airway model. J Aerosol Med. 2004;17(1):51–61
  16. Tal A, Golan H, Grauer N, et al. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J Pediatr. 1996 Apr;128(4):479–484
  17. Amirav I, Balanov I, Gorenberg M, et al. β-Agonist aerosol distribution in respiratory syncytial virus bronchiolitis in infants. J Nucl Med. 2002 Apr;43(4):487–491
  18. Amirav I, Balanov M, Gorenberg M, et al. Nebuliser hood compared to mask in wheezy infants: aerosol therapy without tears!. Arch Dis Child. 2003 Aug;88(8):719–723
  19. Esposito-Festen J, Ates B, van Vliet F, et al. Aerosol delivery to young children by pMDI-spacer: is facemask design important?. Pediatr Allergy Immunol. 2005 Jun;16(4):348–353
  20. Amirav I, Newhouse M. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics. 2001 Aug;108(2):389–394
  21. Smaldone GC, Berg E, Nikander K. Variation in pediatric aerosol delivery: importance of facemask. J Aerosol Med. 2005 Fall;18(3):354–363
  22. Esposito-Festen J, Ates B, van Vliet F, et al. Effect of a facemask leak on aerosol delivery from a pMDI-spacer system. J Aerosol Med. 2004 Spring;17(1):1–6
  23. Erzinger S, Schueepp KG, Brooks-Wildhaber J, et al. Facemasks and aerosol delivery in vivo. J Aerosol Med. 2007;20(s1):S78–S84
  24. Sangwan S, Gurses BK, Smaldone GC. Facemasks and facial deposition of aerosols. Pediatr Pulmonol. 2004 May;37(5):447–452
  25. Dahlstrom K, Thorsson L, Larsson P, et al. Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Ann Allergy Asthma Immunol. 2003;90(2):226–232
  26. Agertoft L, Laulund LW, Harrison LI, et al. Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children. Pediatr Pulmonol. 2003 Mar;35(3):192–199
  27. Szefler SJ, Warner J, Staab D, et al. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: a 6-month, open- label, randomized trial. J Allergy Clin Immunol. 2002 Jul;110(1):45–50
  28. Pedersen S, Warner J, Wahn U, et al. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: an open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics. 2002 Jun;109(6):e92
  29. Luangkhot J, Jauernig A, Balcke, et al. Characterisation of salbutamol solution compared to budesonide suspensions consisting of submicron and micrometer particles in the PARI LC STAR® and a new PARI electronic Nebuliser (e-Flow). DDL XI, London, December 11–12, 2000; Proceedings, p. 14–17.
  30. Bucholski A, Hug M, Keller M. In-vitro equivalence of a generic Ipratropiumbromide inhalation solution versus Atrovent® in two jet nebulisers and two electronic eFlow® nebuliser configurations. In: 16th congress, Tours, France, June 16th–20h, 2007; ISAM 2007.
  31. Coates A, Leung K, Green M, et al. A rapid way to deliver high doses of tobramycin to the airways of adult and pediatric patients with cystic fibrosis (CF). Anaheim: North American Cystic Fibrosis Conference; October 3–6, 2007;
  32. Friedrich F, Keller M, Döhmen H, et al. Comparison of tobramycin serum plasma levels in 5 CF patients after inhalation via a PARI LC PLUS® nebuliser and via eFlow®, a novel electronic inhaler. J Cyst Fibros. 2004;3(Suppl. 1):S64
  33. Shapiro G, Mendelson L, Kraemer MJ, et al. Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid-dependent, persistent asthma. J Allergy Clin Immunol. 1998;102(5):789–796
  34. Kemp JP, Skoner DP, Szefler SJ, et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Asthma Immunol. 1999;83(3):231–239
  35. Baker JW, Mellon M, Wald J, et al. A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. Pediatrics. 1999;103(2):414–421
  36. Leflein JG, Gawchik SM, Galant SP, et al. Safety of budesonide inhalation suspension (Pulmicort Respules) after up to 52 weeks of treatment in infants and young children with persistent asthma. Allergy Asthma Proc. 2001;22(6):359–366
  37. Irani AM, Cruz-Rivera M, Fitzpatrick S, et al. Effects of budesonide inhalation suspension on hypothalamic-pituitary-adrenal-axis function in infants and young children with persistent asthma. Ann Allergy Asthma Immunol. 2002;88(3):306–312
  38. Berger WE, Qaqundah PY, Blake K, et al. Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr. 2005;146(1):91–95
  39. Connett G, Lenney W. Prevention of viral induced asthma attacks using inhaled budesonide. Arch Dis Child. 1993;68:85–87
  40. Svedmyr J, Nyberg E, Asbrink-Nilsson E, et al. Intermittent treatment with inhaled steroids for deterioration of asthma due to upper respiratory tract infectcions. Acta Paediatr. 1995;84:884–888
  41. Wilson NM, Silverman M. Treatment of acute, episodic asthma in preschool children using intermittent high dose inhaled steroids at home. Arch Dis Child. 1990;65:407–410
  42. Nuhõglu Y, Bahececiler NN, Barlan IB, et al. The effectiveness of high-dose inhaled budesonide therapy in the treatment of acute asthma exacerbations in children. Ann Allergy Asthma Immunol. 2001;86:318–322
  43. Everard M. Ethical aspects of using radiolabelling in aerosol research. Arch Dis Child. 2003 Aug;88(8):659–661

PII: S0954-6111(09)00151-6

doi: 10.1016/j.rmed.2009.04.029

Respiratory Medicine
Volume 103, Issue 11 , Pages 1738-1745 , November 2009

Article Tools

* Image Usage & Resolution